Back to News
Market Impact: 0.3
Orbis Medicines Partners With Novo In Up To $1.4 Billion Drug Discovery Deal
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Privately held Orbis Medicines entered a strategic collaboration and licensing agreement with Novo Nordisk to discover and develop next-generation oral therapies for cardiometabolic diseases, including obesity and related metabolic disorders. The partnership expands Novo Nordisk's pipeline efforts in a high-growth obesity-treatment market, though financial terms and development timelines were not disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
NVO0.55
More News
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- New Apple CEO John Ternus chalks up some early wins, but the honeymoon is over
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Oracle files to sell $20 billion in new stock, bonds to finance AI buildout